Antigens and Adjuvants for a New Generation of Vaccines

  • Anthony C. Allison
Part of the NATO ASI Series book series (NSSA, volume 179)


More than a decade has passed since vaccination made possible the global eradication of smallpox. Vaccination has also been remarkably successful in reducing morbidity and mortality due to yellow fever virus in Africa as well as Central and South America. These vaccines, as well as the vaccines developed after the last World War against measles and rubella, contain live attenuated viruses. While there is no question about the efficacy of such vaccines and their safety in the great majority of recipients, they can produce encephalitis or other complications in humans with immunodeficiency. Many persons in developing countries are immuno-deficient because of infections and poor nutrition (Dowd and Heatley, 1984). The high prevalence of human immunodeficiency virus (HIV) in parts of Africa is now recognized. Live bacterial vaccines, e.g. Mycobacterium bovis BCG, can also produce generalized infections in immunocompromised persons. Hence the desirability of developing vaccines based on inactivated viruses or bacteria, or purified antigens, is generally recognized. The question is whether such development is feasible: there is still a widespread belief that only living vaccines can elicit cell-mediated immunity and protection against some infections.


Human Immunodeficiency Virus Anterior Uveitis Pertussis Vaccine Follicular Dendritic Cell Bordetella Pertussis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abbas, A.K., 1988, A reassessment of the mechanisms of antigen-specific T-cell-dependent B-cell activation, Immunol.Today, 9: 89.PubMedCrossRefGoogle Scholar
  2. Allison, A.C., 1978, Macrophage activation and nonspecific immunity, Int.Rev.Exp.Pathol., 18: 303.PubMedGoogle Scholar
  3. Allison, A.C., 1980, Immune responses to polyoma virus and polyoma virus-induced tumors, in: “Viral Oncology”, G. Klein, ed., Raven Press, New York.Google Scholar
  4. Allison, A.C., 1988, The role of monocytes, macrophages, Langerhans cells and follicular dendritic cells in persistent virus infections, in: “Persistent Virus Infections”, C. Lopez and H. Margolis, eds., Alan R. Liss, New York.Google Scholar
  5. Allison, A.C. and Byars, N.E., 1986, An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and cell-mediated immunity, J. Immunol. Methods, 95: 157.PubMedCrossRefGoogle Scholar
  6. Arden, N.H., Patriarca, P.A. and Kendal, A.P., 1986, Experiences in the use and efficacy of influenza vaccine in nursing homes, in: “Options for Control of Influenza”, A.P. Kendal and P.A. Patriarca, eds., Alan R. Liss, New York.Google Scholar
  7. Balfour, B.M., Drexhage, H.A., Kamperdijk, E.W.A. and Hoefsmid, E.C., 1981, Antigen-presenting cells, including Langerhans cells, veiled cells and interdigitating cells, Ciba Foundation Symposium, 84: 281.PubMedGoogle Scholar
  8. Berman, P.W., Gregory, T., Crase, P. and Lasky, L.A., 1985, Protection from genital herpes simplex type 2 infection by vaccination with cloned glycoprotein D, Science, 227: 1490.PubMedCrossRefGoogle Scholar
  9. Bloch, H., 1955, Virulence of mycobacteria, Adv.Tuberc.Res., 6: 49.Google Scholar
  10. Byars, N.E. and Allison, A.C., 1987, Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity, Vaccine, 5: 223.PubMedCrossRefGoogle Scholar
  11. Davies, P. and Allison, A.C., 1976, Secretion of macrophage enzymes in relation to the pathogenesis of chronic inflammation, in: “Immunobiology of the Macrophage”, D.S. Nelson, ed., Academic Press, New York.Google Scholar
  12. Dinarello, C.A., 1986, Multiple biological properties of recombinant human interleukin 1 (beta), Immunobiology, 172: 301.PubMedCrossRefGoogle Scholar
  13. Dowd, P.S. and Heatley, R.V., 1984, The influence of undernutrition on immunity, Clin.Sci., 66: 241.PubMedGoogle Scholar
  14. Dresser, D. and Mitchison, A., 1968, The mechanism of immunologic paralysis, Adv. Immunol., 8: 129.PubMedCrossRefGoogle Scholar
  15. Finkelman, F.D., Katona, I.M., Mosmann, T.R. and Coffman, R.L., 1988a, Interferon-regulates the isotypes of immunoglobulin secreted during in vivo humoral responses, J. Immunol., 140: 1022.PubMedGoogle Scholar
  16. Finkelman, F.D., Katona, I.M., Urban, J., Holmes, J., Ohara, J., Tung, A.S., Sample, J.G. and Paul, W.E., 1988b, IL-4 is required to generate and sustain in vivo IgE responses, J. Immunol., 141: 2335.PubMedGoogle Scholar
  17. Gauldie, J., Richards, C., Harnish, D., Lansdorf, P. and Baumann, H., 1987, Interferon β2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute-phase response in liver cells, Proc.Natl.Acad.Sci.USA, 84: 7251.PubMedCrossRefGoogle Scholar
  18. Geczy, A.F., Alexander, K., Bashir, H.V., Edmonds, J.P., Upfold, L. and Sullivan, J., 1983, HLA-B27, Klebsiella and ankylosing spondylitis: biological and chemical studies, Immunol.Rev., 70: 23.PubMedCrossRefGoogle Scholar
  19. Hayward, A.J., 1982, Immunodeficiency, in: “Clinical Aspects of Immunology”, P.J. Lachmann and D.K. Peters, eds., Blackwell Scientific Publications, 2: 1658, Oxford.Google Scholar
  20. Helle, M., Boeije, L. and Aarden, L.A., 1988, Functional discrimination between interleukin-6 and interleukin-1, Eur.J. Immunol., 18: 1535.PubMedCrossRefGoogle Scholar
  21. Hogle, J.M., Chow, M. and Tilman, D.J., 1985, Three-dimensional structure of poliovirus at 2.9A resolution, Science, 29: 1358.CrossRefGoogle Scholar
  22. Kaminski, M.S., Kitamura, K., Maloney, D.G., Campbell, M.J. and Levy, R., 1986, Importance of antibody isotype in monoclonal anti-idiotype therapy of murine B cell lymphoma. A study of hybridoma class-switch variants, J. Immunol., 136: 1123.PubMedGoogle Scholar
  23. Kenney, J.S., Hughes, B.W., Masada, M. and Allison, A.C., 1989, Evaluation of adjuvants for the production of murine monoclonal antibodies, J. Immunol.Methods (in press).Google Scholar
  24. Klaus, G.G., Humphrey, J.H., Kunkl, A. and Dongworth, D.W., 1980, The follicular dendritic cell: its role in antigen presentation in the generation of immunological memory, Immunol.Rev., 53: 3.PubMedCrossRefGoogle Scholar
  25. Knight, S.C., Krejci, J., Malkovsky, M., Colizzi, V., Gautam, A. and Asherson, G.L., 1985, The role of dendritic cells in the initiation of immune responses to contact sensitizers. I. In vivo exposure to antigen, Cell.Immunol., 94: 427.PubMedCrossRefGoogle Scholar
  26. Knight, S.C., Mertin, J., Stackpole, A. and Clarke, J., 1983, Induction of immune responses in vivo with small numbers of veiled (dendritic) cells, Proc.Natl.Acad.Sci.USA, 80: 6032.PubMedCrossRefGoogle Scholar
  27. Lehman, D.A. and Coffman, R.L., 1988, The effects of IL-4 and IL-5 on the IgA response by murine Peyer’s patch B cell subpopulations, J. Immunol., 141: 2050.Google Scholar
  28. Letvin, N.L., Daniel, M.D., King, N.W., Kiyotaki, M., Kannagi, N., Chalifoux, L.V., Sehgal, P.K., Desrosiers, R.C., Arthur, L.O. and Allison, A.C., 1987, AIDS-like disease in macaques induced by simian immunodeficiency virus: a vaccine trial, in: “Vaccines”, R.M. Chanock, R.A. Lener, F. Braun and H.S. Ginasky, eds., Cold Spring Harbor, New York.Google Scholar
  29. MacKay, P., Lees, J. and Murray, K., 1981, The conversion of hepatitis B core antigen synthesized in E. coli into e antigen, J.Med.Virol., 8: 237.PubMedCrossRefGoogle Scholar
  30. Milich, D.R. and Chisari, F.V., 1982, Genetic regulation of the immune response to hepatitis B surface antigen (HBsAg). I. H-2 restriction of the murine humoral immune response to the a and d determinants of HBsAg, J. Immunol., 129: 320.PubMedGoogle Scholar
  31. Morris, A.G., Lin, Y-L. and Askonas, B.A., 1982, Immune interferon release when a cloned cytotoxin T-cell line meets its correct influenza-infected target, Nature, 295: 150.PubMedCrossRefGoogle Scholar
  32. Murray, K., Bruce, S.A., Hinnen, A., Wingfield, P., van Erd, P.M., de Reus, A. and Schellekens, H., 1984, Hepatitis B virus antigens made in microbial cells immunize against viral infection, EMBO J., 3: 645.PubMedGoogle Scholar
  33. Nash, A.A. and Gell, P.H.G., 1983, Membrane phenotype of murine effector and suppressor cells involved in delayed hypersensitivity and protective immunity to herpes simplex virus, Cell.Immunol., 75: 348.PubMedCrossRefGoogle Scholar
  34. Nicholson, K.G., Tyrrell, D.A.J., Harrison, P., Potter, C.W., Jennings, R.Google Scholar
  35. Clark, A., Schild, G.C., Wood, J.M., Yells, R., Seagrott, V., Huggens, A. and Anderson, S.G., 1979, Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1 ) vaccine: serological and clinical reactions, J. Biol. Stand., 7: 123.PubMedCrossRefGoogle Scholar
  36. Oppenheim, J.J., Togawa, A., Chedid, L. and Mizel, S., 1980, Components of mycobacteria and muramyl dipeptide with adjuvant activity induce lymphocyte-activating factor, Cell.Immunol., 50: 71.PubMedCrossRefGoogle Scholar
  37. Pène, J., Rousset, F., Briere, F., Chretien, I., Paliard, X., Banchereau, J., Spits, H. and DeVries, J.E., 1988, IgE production by normal human B cells induced by alloreactive T cell clones is mediated by IL-4 and suppressed by IFN-T, J. Immunol., 141: 1218.PubMedGoogle Scholar
  38. Potter, M. and Boyce, C.R., 1962, Induction of plasma cell neoplasms in Balb/c strain mice with mineral oil and mineral oil adjuvants, Nature, 193: 1086.PubMedCrossRefGoogle Scholar
  39. Rager-Zisman, B. and Allison, A.C., 1976, Mechanism of immunologic resistance to herpes simplex virus (HSV-1) infection, J. Immunol., 116: 35.PubMedGoogle Scholar
  40. Reichmann, L., Clark, M., Waldmann. H. and Winter, G., 1988, Reshaping human antibodies for therapy, Nature, 332: 323.CrossRefGoogle Scholar
  41. Ron, Y. and Sprent, J., 1987, T-cell priming in vivo: a major role for B-cells in presenting antigen to T-cells in lymph nodes, J. Immunol., 138: 2848.PubMedGoogle Scholar
  42. Scolnick, E.M., McLean, A.A., West, D.J., McAleer, W.J., Miller, W.J. and Bunyak, E.B., 1984, Clinical evaluation in healthy adults of a hepatitis B vaccine made by recombinant DNA, J.A.M.A., 251: 2812.PubMedCrossRefGoogle Scholar
  43. Snapper, C.M., Finkelman, F.D. and Paxil, W.E., 1988, Differential regulation of IgGl and IgE synthesis by interleukin-4, J.Exp.Med., 167: 183.PubMedCrossRefGoogle Scholar
  44. Steinman, R.M. and Nussenzweig, M.C, 1980, Dendritic cells: features and functions, Immunol.Rev., 53: 127.PubMedCrossRefGoogle Scholar
  45. Steplewski, Z., Spira, G., Blasczyc, M., Lubeck, M.D., Radlmuch, A., Illges, H., Herlyn, D., Rajewsky, K. and Scharff, M., 1985, Isolation and characterization of anti-monosialoganglioside monoclonal antibody 19-9S class switch variants, Proc.Natl.Acad.Sci., USA, 82: 3653.CrossRefGoogle Scholar
  46. Szakal, A.K., Kosco, M.H. and Tew, J.G., 1988, A novel in vivo follicular dendritic cells — its role in antigen presentation and in the generation of immunological memory, J. Immunol., 140: 341.PubMedGoogle Scholar
  47. Turk, J.L. and Parker, D., 1977, Granuloma formation in normal guinea pigs injected intradermally with aluminum and zirconium compounds, J.Invest.Dermatol., 68: 336.PubMedCrossRefGoogle Scholar
  48. Uhkeless, J.C, Scigliano, E. and Freedman, V.H., 1988, Structure and function of human and murine receptors for IgG, Ann.Rev.Immunol., 6: 251.CrossRefGoogle Scholar
  49. Valenzuela, P., Medina, A., Rutter, W.J., Annerer, A. and Hall, B.D., 1983, Synthesis and assembly of hepatitis B virus surface antigen particles in yeast, Nature, 291: 503.Google Scholar
  50. Waters, R.V., Terrell, T.G. and Jones, G.H., 1986, Uveitis induction in the rabbit by muramyl dipeptides, Infect.Immun., 51: 816.PubMedGoogle Scholar
  51. Walker, B.D., Fiemer, C, Paradis, T.J., Fuller, T.C, Hirsch, M.S., Schooley, R.T. and Moss, B., 1988, HIV-1 reverse transcriptase is a target for cytotoxic T-lymphocytes in infected individuals, Science, 240: 64.PubMedCrossRefGoogle Scholar
  52. Wechsler, D.S. and Konghshavn, P.A.L., 1986, Heat-labile antibodies effects cure of Trypanosoma musculi infection in C57BL/6 mice, J. Immunol., 137: 2968.PubMedGoogle Scholar
  53. White, R.G., 1976, The adjuvant effect of microbiol products on the immune response, Ann.Rev.Microbiol., 30: 579.CrossRefGoogle Scholar
  54. Wiley, D.C, Wilson, I.A. and Skehel, J.J., 1981, Structural identification of the antibody binding sites of influenza haemagglutinin and their involvement in antigenic variation, Nature, 289: 373.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • Anthony C. Allison
    • 1
  1. 1.Syntex ResearchPalo AltoUSA

Personalised recommendations